Advertisement
Screener

Prime Medicine, Inc. (PRME) Graph

PRME Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $33.40M; Operating expenses $44.44M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $34.10M; Operating expenses $51.51M; Income tax (m).
  • 2025-12-31: Revenue $838.00K*; Research and development $34.71M*; Operating expenses $49.45M*; Income tax (m).
  • 2025-09-30: Revenue $1.23M; Research and development $43.99M; Operating expenses $55.20M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$33.40M$44.44M(m)-$42.11M
2026-03-31(m)$34.10M$51.51M(m)-$49.12M
2025-12-31$838.00K*$34.71M*$49.45M*(m)-$46.08M*
2025-09-30$1.23M$43.99M$55.20M(m)-$50.58M
2025-06-30$1.11M$41.38M$54.49M$0.00-$52.59M
2025-03-31$1.45M$40.56M$53.85M$0.00-$51.89M
2024-09-30$209.00K$40.34M$54.44M$0.00-$52.52M
2024-06-30$0.00$43.07M$55.67M-$134.00K-$55.33M
2024-03-31$591.00K$37.77M$48.93M$134.00K-$45.76M
2023-09-30$0.00$40.97M$51.46M-$108.00K-$50.71M
2023-06-30$0.00$34.60M$45.26M$31.00K-$42.38M
2023-03-31$0.00$30.88M$40.03M-$202.00K-$39.40M
2022-09-30(m)$25.05M$31.66M$212.00K-$29.35M
2022-06-30(m)(m)$26.30M-$442.00K-$29.35M
2022-03-31(m)$13.68M$19.90M-$532.00K-$23.84M
2021-09-30(m)$7.40M$10.43M-$2.37M-$16.41M
2021-06-30(m)(m)(m)(m)$616.00K
2021-03-31(m)(m)(m)(m)-$86.66M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$67.50M$95.95M(m)-$91.23M
2025-06-30$2.57M$81.94M$108.34M$0.00-$104.48M
2024-06-30$591.00K$80.84M$104.60M$0.00-$101.09M
2023-06-30$0.00$65.48M$85.29M-$171.00K-$81.78M
2022-06-30(m)(m)$46.20M-$974.00K-$53.19M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$3.79M$125.93M$163.54M(m)-$155.06M
2024-09-30$800.00K$121.19M$159.04M$0.00-$153.61M
2023-09-30$0.00$106.45M$136.75M-$279.00K-$132.49M
2022-09-30(m)$57.66M$77.86M-$762.00K-$82.54M
2021-09-30(m)$17.66M$24.40M-$1.87M-$102.46M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$4.63M$160.64M$212.98M$0.00-$201.14M
2024-12-31$2.98M$155.29M$205.45M$0.00-$195.88M
2023-12-31$0.00$147.91M$204.79M-$279.00K-$198.13M
2022-12-31$0.00$86.72M$116.54M-$948.00K-$121.82M
2021-12-31$0.00$70.55M$84.47M-$486.00K-$165.37M
2020-12-31$5.21M$2.98M$6.14M$1.87M-$3.41M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Allogene Therapeutics, Inc. (ALLO)United States$0.574B-4.33
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Entera Bio Ltd. (ENTX)$0.485B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Aura Biosciences, Inc. (AURA)United States$0.639B-5.61
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Scribe Therapeutics, Inc. (SCTX)United States$0.410B